Xiao-Wen Lu1,2,3,4, Hua Guo5, Jing-Rong Sun1,2,3,4, Qiang-Li Dong1,2,3,4, Fu-Tao Zhao5, Xu-Hong Liao6,7,8, Li Zhang1,2,3,4, Yan Zhang1,2,3,4, Wei-Hui Li1,2,3,4, Ze-Xuan Li1,2,3,4, Tie-Bang Liu9, Yong He6,7,8, Ming-Rui Xia6,7,8, Ling-Jiang Li1,2,3,4,9. 1. Mental Health Institute, The Second Xiangya Hospital, Central South University, Changsha, China. 2. National Clinical Research Center on Mental Disorders, Changsha, China. 3. National Technology Institute on Mental Disorders, Changsha, China. 4. Hunan Key Laboratory of Psychiatry and Mental Health, Changsha, China. 5. Zhumadian Psychiatry Hospital, Zhumadian, China. 6. State Key Laboratory of Cognitive Neuroscience and Learning, Beijing Normal University, Beijing, China. 7. Beijing Key Laboratory of Brain Imaging and Connectomics, Beijing Normal University, Beijing, China. 8. IDG/McGovern Institute for Brain Research, Beijing Normal University, Beijing, China. 9. Shenzhen Mental Health Center, Shenzhen, China.
Abstract
AIMS: This study assessed whether antidepressant drug treatment has a common effect on gray matter (GM) volume in MDD patients with and without childhood maltreatment (CM). METHODS: T1-weighted structural magnetic resonance imaging data were collected from 168 participants, including 51 MDD patients with CM, 31 MDD patients without CM, 48 normal controls with CM, and 38 normal controls without CM. MDD patients received 6 months of treatment with paroxetine, and 24 patients with CM, and 16 patients without CM received a second MRI scan. A whole-brain voxel-based morphometry approach was used to estimate GM volume in each participant at two time points. Two-way analysis of variance (ANOVA) was used to determine the effects of MDD and CM on GM volume at baseline. Repeated measures two-way ANOVA was used to determine the treatment-by-CM interactive effect and main effect of treatment during paroxetine treatment. We further investigated the relationship between GM volume and clinical variables. RESULTS: At baseline, significant MDD-by-CM interactive effects on GM volume were mainly observed in the left parahippocampal gyrus, left entorhinal cortex, and left cuneus. GM volume was significantly lower mainly in the right middle temporal gyrus in patients with MDD than in normal controls. We did not find any significant treatment-by-CM interactive effects. However, a treatment-related increase in GM was found in the right middle temporal gyrus in both MDD groups. CONCLUSIONS: These results suggest that paroxetine treatment operates via a shared neurobiological mechanism in MDD patients with and without CM.
AIMS: This study assessed whether antidepressant drug treatment has a common effect on gray matter (GM) volume in MDDpatients with and without childhood maltreatment (CM). METHODS: T1-weighted structural magnetic resonance imaging data were collected from 168 participants, including 51 MDDpatients with CM, 31 MDDpatients without CM, 48 normal controls with CM, and 38 normal controls without CM. MDDpatients received 6 months of treatment with paroxetine, and 24 patients with CM, and 16 patients without CM received a second MRI scan. A whole-brain voxel-based morphometry approach was used to estimate GM volume in each participant at two time points. Two-way analysis of variance (ANOVA) was used to determine the effects of MDD and CM on GM volume at baseline. Repeated measures two-way ANOVA was used to determine the treatment-by-CM interactive effect and main effect of treatment during paroxetine treatment. We further investigated the relationship between GM volume and clinical variables. RESULTS: At baseline, significant MDD-by-CM interactive effects on GM volume were mainly observed in the left parahippocampal gyrus, left entorhinal cortex, and left cuneus. GM volume was significantly lower mainly in the right middle temporal gyrus in patients with MDD than in normal controls. We did not find any significant treatment-by-CM interactive effects. However, a treatment-related increase in GM was found in the right middle temporal gyrus in both MDD groups. CONCLUSIONS: These results suggest that paroxetine treatment operates via a shared neurobiological mechanism in MDDpatients with and without CM.
Authors: Andrée M Cusi; Anthony Nazarov; Katherine Holshausen; Glenda M Macqueen; Margaret C McKinnon Journal: J Psychiatry Neurosci Date: 2012-05 Impact factor: 6.186
Authors: Meena Vythilingam; Christine Heim; Jeffrey Newport; Andrew H Miller; Eric Anderson; Richard Bronen; Marijn Brummer; Lawrence Staib; Eric Vermetten; Dennis S Charney; Charles B Nemeroff; J Douglas Bremner Journal: Am J Psychiatry Date: 2002-12 Impact factor: 18.112
Authors: Eric Vermetten; Meena Vythilingam; Steven M Southwick; Dennis S Charney; J Douglas Bremner Journal: Biol Psychiatry Date: 2003-10-01 Impact factor: 13.382
Authors: Shefali Miller; Lisa M McTeague; Anett Gyurak; Brian Patenaude; Leanne M Williams; Stuart M Grieve; Mayuresh S Korgaonkar; Amit Etkin Journal: Depress Anxiety Date: 2015-04-27 Impact factor: 6.505
Authors: Beatrix Krause-Sorio; Prabha Siddarth; Lisa Kilpatrick; Kelsey T Laird; Michaela M Milillo; Linda Ercoli; Katherine L Narr; Helen Lavretsky Journal: J Affect Disord Date: 2020-05-24 Impact factor: 4.839
Authors: Tania M Pollok; Anna Kaiser; Eline J Kraaijenvanger; Maximilian Monninger; Daniel Brandeis; Tobias Banaschewski; Simon B Eickhoff; Nathalie E Holz Journal: Neurosci Biobehav Rev Date: 2022-02-18 Impact factor: 9.052